Table 3. The binding scores, RMSD values, distance, and receptor interactions of the most promising compounds (1, 3, 5, 6, 7, 8, and 9) were compared to the docked ligand [Acarbose and Evogliptin] and 5J7 as a reference for anti-diabetic evaluation.
| Comp | Score (kcal mol−1) | RMSD | Interacting residues | ||||
|---|---|---|---|---|---|---|---|
| Ligand | Receptor | Interactions | Distance (Å) | E (kcal mol−1) | |||
| 5J7 (reference) | −9.04865932 | 1.966 | O 28 | ND1 HIS 305 (A) | H-acceptor | 2.93 | −2.5 |
| O 62 | OD1 ASP 300 (A) | H-donor | 2.85 | −2.0 | |||
| C 75 | OE2 GLU 233 (A) | H-donor | 3.41 | −0.5 | |||
| Acarbose | −8.39953136 | 1.470 | O 81 | OE1 GLU 233 (A) | H-donor | 3.27 | −1.3 |
| C 55 | 5-Ring TRP 59 (A) | H-pi | 3.92 | −0.6 | |||
| C 68 | 6-Ring TYR 62 (A) | H-pi | 4.49 | −0.7 | |||
| O 86 | 5-Ring HIS 101 (A) | H-pi | 4.24 | −1.0 | |||
| Evogliptin | −6.45007515 | 1.603 | C 36 | 6-Ring TYR 62 (A) | H-pi | 4.24 | −1.0 |
| 1 | −6.04776144 | 1.365 | O 11 | OE2 GLU 233 (A) | H-donor | 2.70 | −1.7 |
| N 5 | 6-Ring TYR 62 (A) | H-pi | 3.85 | −0.8 | |||
| 3 | −5.58074379 | 0.529 | N 35 | 6-Ring TYR 62 (A) | H-pi | 4.20 | −1.8 |
| 5 | −5.26979733 | 1.554 | N 11 | OE2 GLU 233 (A) | H-donor | 2.98 | −4.5 |
| N 33 | OG1 THR 163 (A) | H-donor | 3.04 | −1.5 | |||
| N 16 | NE2 HIS 299 (A) | H-acceptor | 3.63 | −1.0 | |||
| 6 | −6.6096797 | 1.217 | N 59 | OE2 GLU 233 (A) | H-donor | 2.99 | −3.4 |
| C 49 | 5-Ring TRP 59 (A) | H-pi | 4.23 | −0.5 | |||
| 7 | −5.78755617 | 1.989 | N 43 | OE1 GLU 233 (A) | H-donor | 2.97 | −3.9 |
| 8 | −5.62768507 | 1.188 | N 13 | OE2 GLU 233 (A) | H-donor | 2.90 | −8.5 |
| O 30 | NH2 ARG 195 (A) | H-acceptor | 2.99 | −2.4 | |||
| N 16 | 6-Ring TYR 62 (A) | H-pi | 4.20 | −0.8 | |||
| 9 | −5.00731277 | 0.991 | N 23 | OE2 GLU 233 (A) | H-donor | 2.88 | −8.8 |